CYRX Share Price Performance
US$8.77
3.33 (61.21%)
33.7% undervalued intrinsic discount
US$13.22
Fair Value
Price US$8.77
AnalystConsensusTarget US$13.22
AnalystHighTarget US$16.00
AnalystLowTarget US$9.50
Fair ValueUS$13.22
Share Pricen/a
Cryoport, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
CYRX Community Narratives
AN
Fair Value US$13.22 33.7% undervalued intrinsic discount
Cold Chain Expansion Will Support Cell And Gene Therapies
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$16 45.2% undervalued intrinsic discount
Digitalization And Secular Trends Will Expand Biotech Cold Chain Services
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$9.5 7.7% undervalued intrinsic discount
Rising Biopharma Regulations Will Crimp Expansion But Foster Recovery
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Rising Biopharma Regulations Will Crimp Expansion But Foster Recovery
Key Takeaways Advances in therapy methods and industry commoditization could limit Cryoport's market and erode its differentiation and margins over time. Customer concentration, regulatory shifts, and high fixed costs from ongoing investments expose earnings to disruption and may pressure profitability if growth slows.Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$9.5
7.7% undervalued intrinsic discount
Fair Value
Profit Margin
15.52%
Future PE
17.15x
Price in 2029
US$12.31
Cold Chain Expansion Will Support Cell And Gene Therapies
Key Takeaways Growing demand in cell and gene therapy logistics, along with expanding partnerships, positions Cryoport for sustained revenue growth and improved operational efficiency. Diversification into new technologies and services reduces risk, enhances competitive edge, and supports stronger long-term earnings and profit margins.Read more
55
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$13.22
33.7% undervalued intrinsic discount
Fair Value
Profit Margin
15.69%
Future PE
24.93x
Price in 2029
US$16.81
Digitalization And Secular Trends Will Expand Biotech Cold Chain Services
Key Takeaways Cryoport's leading position in cell and gene therapy logistics, bolstered by global partnerships, drives strong market expansion and outsized long-term revenue potential. Operational scale, high-demand services, and technology integration are expected to drive significant margin gains and enhanced shareholder value.Read more
7
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$16
45.2% undervalued intrinsic discount
Fair Value
Profit Margin
14.21%
Future PE
35.45x
Price in 2028
US$20.22
Trending Discussion
Recently Updated Narratives
AN
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Fair Value: US$9.5 7.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CYRX: Share Repurchases And Higher Margin Outlook Will Drive Future Upside
Fair Value: US$13.22 33.7% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Digitalization And Secular Trends Will Expand Biotech Cold Chain Services
Fair Value: US$16 45.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cryoport, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.84
- 47.14%
- -23.82%
- 37.1%
About CYRX
- Founded
- 1999
- Employees
- 688
- CEO
- WebsiteView website
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company’s products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.
